Wed, Jul 9, 2014, 10:52 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • solantey@sbcglobal.net solantey Oct 21, 2012 10:23 AM Flag

    Mannkind - MNKD - Consider Buying A Few Shares Under $2.00

    The announcement that Mannkind has issued a new secondary to raise funds has created a buying opportunity.

    Mannkind's insulin drug, Afrezza, could receive F.D.A. approval as early as September,2013 if it is granted "priority review" status.

    With $1.6 billion in tax-loss carry forwards and insulin inventory to produce $10,000,000,000 worth of Afrezza the company in a potential takeover target which may be why the company's billionaire C.E.O., Al Mann, converted over $100 million in debt owed to him by the company at $2.59/share last week.

    A "big-pharma" partnership could happen at any time.

    Consider buying a few shares below $2.00 before the approval run-up begins.

 
NBIX
14.43+0.20(+1.41%)Jul 9 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.